Bone marrow NG2
Journal
Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
entrez:
7
1
2022
pubmed:
8
1
2022
medline:
8
1
2022
Statut:
ppublish
Résumé
In the bone marrow (BM) microenvironment, where breast cancer (BC) disseminated tumour cells (DTCs) can remain dormant for decades, NG2
Identifiants
pubmed: 34993493
doi: 10.1038/s43018-021-00179-8
pmc: PMC8730384
mid: NIHMS1675122
pii: 10.1038/s43018-021-00179-8
doi:
Substances chimiques
Nestin
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
327-339Subventions
Organisme : NCI NIH HHS
ID : R01 CA244780
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK112976
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218024
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL069438
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218578
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA216248
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA109182
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK116312
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL145064
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL126705
Pays : United States
Organisme : NCI NIH HHS
ID : K22 CA196750
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK056638
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA196521
Pays : United States
Références
Chaffer, C. L. & Weinberg, R. A. A perspective on cancer cell metastasis. Science 331, 1559–1564 (2011).
doi: 10.1126/science.1203543
Sherry, M. M., Greco, F. A., Johnson, D. H. & Hainsworth, J. D. Metastatic breast cancer confined to the skeletal system. An indolent disease. Am. J. Med. 81, 381–386 (1986).
doi: 10.1016/0002-9343(86)90286-X
Engel, J. et al. The process of metastasisation for breast cancer. Eur. J. Cancer 39, 1794–1806 (2003).
doi: 10.1016/S0959-8049(03)00422-2
Husemann, Y. et al. Systemic spread is an early step in breast cancer. Cancer Cell 13, 58–68 (2008).
doi: 10.1016/j.ccr.2007.12.003
Sanger, N. et al. Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int. J. Cancer https://doi.org/10.1002/ijc.25895 (2011).
Braun, S. et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJM200002243420801 (2000).
Chéry, L. et al. Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget 5, 9939–9951 (2014).
doi: 10.18632/oncotarget.2480
Borgen, E. et al. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients. Breast Cancer Res. https://doi.org/10.1186/s13058-018-1049-0 (2018).
Naume, B. et al. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer. J. Clin. Oncol. 32, 3848–3857 (2014).
doi: 10.1200/JCO.2014.56.9327
Bragado, P. et al. TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling. Nat. Cell Biol. 15, 1351–1361 (2013).
doi: 10.1038/ncb2861
Carlson, P. et al. Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. Nat. Cell Biol. https://doi.org/10.1038/s41556-018-0267-0 (2019).
Johnson, R. W. et al. Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat. Cell Biol. 18, 1078–1089 (2016).
doi: 10.1038/ncb3408
Kobayashi, A. et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J. Exp. Med. 208, 2641–2655 (2011).
doi: 10.1084/jem.20110840
Gao, H. et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 150, 764–779 (2012).
doi: 10.1016/j.cell.2012.06.035
Taichman, R. S. et al. GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS ONE 8, e61873 (2013).
doi: 10.1371/journal.pone.0061873
Yumoto, K. et al. Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow. Sci. Rep. 6, 36520 (2016).
doi: 10.1038/srep36520
Jung, Y. et al. Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow. Oncotarget 7, 25698–25711 (2016).
doi: 10.18632/oncotarget.8365
Yue, X. et al. Leukemia inhibitory factor promotes EMT through STAT3- dependent miR-21 induction. Oncotarget https://doi.org/10.18632/oncotarget.6756 (2015).
Agarwal, P. et al. Mesenchymal niche-specific expression of Cxcl12 controls quiescence of treatment-resistant leukemia stem cells. Cell Stem Cell 24, 769–784 (2019).
doi: 10.1016/j.stem.2019.02.018
Ghajar, C. M. et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 15, 807–817 (2013).
doi: 10.1038/ncb2767
Lawson, M. A. et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat. Commun. https://doi.org/10.1038/ncomms9983 (2015).
Yu-Lee, L. Y. et al. Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFbRIII–p38MAPK–pS249/ T252RB pathway. Cancer Res. 78, 2911–2924 (2018).
doi: 10.1158/0008-5472.CAN-17-1051
Cackowski, F. C. & Taichman, R. S. Parallels between hematopoietic stem cell and prostate cancer disseminated tumor cell regulation. Bone. 119, 82–86 (2019).
doi: 10.1016/j.bone.2018.02.025
Shiozawa, Y. et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 121, 1298–1312 (2011).
doi: 10.1172/JCI43414
Wilson, A. et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 135, 1118–1129 (2008).
doi: 10.1016/j.cell.2008.10.048
Pinho, S. & Frenette, P. S. Haematopoietic stem cell activity and interactions with the niche. Nat. Rev. Mol. Cell Biol. 20, 303–320 (2019).
doi: 10.1038/s41580-019-0103-9
Kunisaki, Y. et al. Arteriolar niches maintain haematopoietic stem cell quiescence. Nature 502, 637–643 (2013).
doi: 10.1038/nature12612
Hanoun, M. et al. Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell Niche. Cell Stem Cell (2014) https://doi.org/10.1016/j.stem.2014.06.020
Maryanovich, M. et al. Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche. Nat. Med. https://doi.org/10.1038/s41591-018-0030-x (2018).
Harper, K. L. et al. Mechanism of early dissemination and metastasis in Her2
Pinho, S. et al. PDGFR and CD51 mark human nestin
doi: 10.1084/jem.20122252
Ranganathan, A. C., Adam, A. P., Zhang, L. & Aguirre-Ghiso, J. A. Tumor cell dormancy induced by p38SAPK and ER-stress signaling: An adaptive advantage for metastatic cells? Cancer Biol. Ther. https://doi.org/10.4161/cbt.5.7.2968 (2006).
Fluegen, G. et al. Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments. Nat. Cell Biol. 19, 120–132 (2017).
doi: 10.1038/ncb3465
Sosa, M. S. et al. NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes. Nat. Commun. 6, 1–14 (2015).
doi: 10.1038/ncomms7170
Männ, L. et al. CD11c.DTR mice develop a fatal fulminant myocarditis after local or systemic treatment with diphtheria toxin. Eur. J. Immunol. https://doi.org/10.1002/eji.201546245 (2016).
Christiaansen, A. F., Boggiatto, P. M. & Varga, S. M. Limitations of Foxp3
Bennett, C. L. et al. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J. Cell Biol. https://doi.org/10.1083/jcb.200501071 (2005).
Xu, C. et al. Stem cell factor is selectively secreted by arterial endothelial cells in bone marrow. Nat. Commun. https://doi.org/10.1038/s41467-018-04726-3 (2018).
Tikhonova, A. N. et al. The bone marrow microenvironment at single-cell resolution. Nature https://doi.org/10.1038/s41586-019-1104-8 (2019).
Vukicevic, S., Latin, V., Chen, P., Batorsky, R. & Reddi, A. H. Localization of osteogenic protein-1 (bone morphogenetic protein-7) during human embryonic development: High affinity binding to basement membranes. Biochem. Biophys. Res. Commun. 198, 693–700 (1994).
doi: 10.1006/bbrc.1994.1100
Gregory, K. E. et al. The prodomain of BMP-7 targets the BMP-7 complex to the extracellular matrix. J. Biol. Chem. 280, 27970–27980 (2005).
doi: 10.1074/jbc.M504270200
Nakahara, F. et al. Engineering a haematopoietic stem cell niche by revitalizing mesenchymal stromal cells. Nat. Cell Biol. https://doi.org/10.1038/s41556-019-0308-3 (2019).
Aguirre-Ghiso, J. A., Ossowski, L. & Rosenbaum, S. K. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res. 64, 7336–7345 (2004).
doi: 10.1158/0008-5472.CAN-04-0113
Regot, S., Hughey, J. J., Bajar, B. T., Carrasco, S. & Covert, M. W. High-sensitivity measurements of multiple kinase activities in live single cells. Cell 157, 1724–1734 (2014).
doi: 10.1016/j.cell.2014.04.039
Oki, T. et al. A novel cell-cycle-indicator, mVenus-p27K. Sci. Rep. 4, 4012 (2014).
doi: 10.1038/srep04012
Asada, N. et al. Differential cytokine contributions of perivascular haematopoietic stem cell niches. Nat. Cell Biol. https://doi.org/10.1038/ncb3475 (2017).
Zhou, B. O., Yue, R., Murphy, M. M., Peyer, J. G. & Morrison, S. J. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell https://doi.org/10.1016/j.stem.2014.06.008 (2014).
Paget, S. The distribution of secondary growths in cancer of the breast. Lancet https://doi.org/10.1016/S0140-6736(00)49915-0 (1889).
Yang, Y. et al. Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis. Oncotarget 8, 30621–30643 (2017).
doi: 10.18632/oncotarget.15695
Boudreau, N. & Bissell, M. J. Extracellular matrix signaling: Integration of form and function in normal and malignant cells. Curr. Opin. Cell Biol. 10, 640–646 (1998).
doi: 10.1016/S0955-0674(98)80040-9
Kenny, P. A. & Bissell, M. J. Tumor reversion: Correction of malignant behavior by microenvironmental cues. Int. J. Cancer 107, 688–695 (2003).
doi: 10.1002/ijc.11491
Turley, R. S. et al. The type III transforming growth factor-β receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res. 67, 1090–1098 (2007).
doi: 10.1158/0008-5472.CAN-06-3117
Ajiboye, S., Sissung, T. M., Sharifi, N. & Fig, W. D. More than an accessory: Implications of type III transforming growth factor-β receptor loss in prostate cancer. BJU Int. 105, 913–916 (2010).
doi: 10.1111/j.1464-410X.2009.08999.x
Dong, M. et al. The type III TGF-β receptor suppresses breast cancer progression. J. Clin. Invest. 117, 206–217 (2007).
doi: 10.1172/JCI29293
Kim, I. Y. et al. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 23, 7651–7659 (2004).
doi: 10.1038/sj.onc.1207924
Singh, A. et al. Angiocrine signals regulate quiescence and therapy resistance in bone metastasis. JCI Insight https://doi.org/10.1172/jci.insight.125679 (2019).
Mignone, J. L., Kukekov, V., Chiang, A. S., Steindler, D. & Enikolopov, G. Neural stem and progenitor cells in nestin-GFP transgenic mice. J. Comp. Neurol. 469, 311–324 (2004).
doi: 10.1002/cne.10964
Ishtiaq Ahmed, A. S., Bose, G. C., Huang, L. & Azhar, M. Generation of mice carrying a knockout-first and conditional-ready allele of transforming growth factor β2 gene. Genesis 52, 817–826 (2014).
doi: 10.1002/dvg.22795
Ossowski, L. & Reich, E. Changes in malignant phenotype of a human carcinoma conditioned by growth environment. Cell 33, 323–333 (1983).
doi: 10.1016/0092-8674(83)90414-2